Daniel I. Feig

Daniel I. Feig

Auto-generated profile, based on publicly available information

Daniel I. Feig

University of Alabama, Birmingham

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2008 in New England Journal of Medicine
Verified
Journal Article
Closed access
DFDaniel I. Feig
Daniel I. Feig
DKDuk-Hee Kang
Duk-Hee Kang
RJRichard J. Johnson
Richard J. Johnson
This review summarizes relevant studies concerning uric acid and possible links to hypertension, renal disease, and cardiovascular disease. Whether uric acid is an independent risk factor for such diseases is still a point of debate. Current evidence is presented.

1 June 2003 in Hypertension
Verified
Journal Article
Closed access
Richard J JohnsonRichard J Johnson
Richard J Johnson
DKDuk-Hee Kang
Duk-Hee Kang
DFDaniel Feig
Daniel Feig
SKSalah Kivlighn
Salah Kivlighn
JKJohn Kanellis
John Kanellis
MMMarilda Mazzali
Marilda Mazzali
Hyperuricemia is associated with hypertension, vascular disease, renal disease, and cardiovascular events. In this report, we review the epidemiologic evidence and potential mechanisms for this association. We also summarize experimental studies that demonstrate that uric acid is not inert but may have both beneficial functions (acting as an antioxidant) as well as detrimental actions (to stimulate vascular smooth muscle cell proliferation and induce endothelial dysfunction). A recently developed experimental model of mild hyperuricemia also provides the first provocative evidence that uric acid may have a pathogenic role in the development of hypertension, vascular disease, and renal disease. Thus, it is time to reevaluate the role of uric acid as a risk factor for cardiovascular disease and hypertension and to design human studies to address this controversy.

1 March 2006 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Closed access
PDF file
TNTakahiko Nakagawa
Takahiko Nakagawa
HHHanbo Hu
Hanbo Hu
SZSergey Zharikov
Sergey Zharikov
KTKatherine R. Tuttle
Katherine R. Tuttle
RSRobert A. Short
Robert A. Short
Richard J JohnsonRichard J Johnson
Richard J Johnson
The worldwide epidemic of metabolic syndrome correlates with an elevation in serum uric acid as well as a marked increase in total fructose intake (in the form of table sugar and high-fructose corn syrup). Fructose raises uric acid, and the latter inhibits nitric oxide bioavailability. Because insulin requires nitric oxide to stimulate glucose uptake, we hypothesized that fructose-induced hyperuricemia may have a pathogenic role in metabolic syndrome. Four sets of experiments were performed. First, pair-feeding studies showed that fructose, and not dextrose, induced features (hyperinsulinemia, hypertriglyceridemia, and hyperuricemia) of metabolic syndrome. Second, in rats receiving a high-fructose diet, the lowering of uric acid with either allopurinol (a xanthine oxidase inhibitor) or benzbromarone (a uricosuric agent) was able to prevent or reverse features of metabolic syndrome. In particular, the administration of allopurinol prophylactically prevented fructose-induced hyperinsulinemia (272.3 vs.160.8 pmol/l, P < 0.05), systolic hypertension (142 vs. 133 mmHg, P < 0.05), hypertriglyceridemia (233.7 vs. 65.4 mg/dl, P < 0.01), and weight gain (455 vs. 425 g, P < 0.05) at 8 wk. Neither allopurinol nor benzbromarone affected dietary intake of control diet in rats. Finally, uric acid dose dependently inhibited endothelial function as manifested by a reduced vasodilatory response of aortic artery rings to acetylcholine. These data provide the first evidence that uric acid may be a cause of metabolic syndrome, possibly due to its ability to inhibit endothelial function. Fructose may have a major role in the epidemic of metabolic syndrome and obesity due to its ability to raise uric acid.

1 October 2007 in The American Journal of Clinical Nutrition
Verified
Journal Article
Closed access
Richard J JohnsonRichard J Johnson
Richard J Johnson
MSMark S Segal
Mark S Segal
YSYuri Sautin
Yuri Sautin
TNTakahiko Nakagawa
Takahiko Nakagawa
DFDaniel I Feig
Daniel I Feig
LLLaura Gabriela Sanchez Lozada
Laura Gabriela Sanchez Lozada
Currently, we are experiencing an epidemic of cardiorenal disease characterized by increasing rates of obesity, hypertension, the metabolic syndrome, type 2 diabetes, and kidney disease. Whereas excessive caloric intake and physical inactivity are likely important factors driving the obesity epidemic, it is important to consider additional mechanisms. We revisit an old hypothesis that sugar, particularly excessive fructose intake, has a critical role in the epidemic of cardiorenal disease. We also present evidence that the unique ability of fructose to induce an increase in uric acid may be a major mechanism by which fructose can cause cardiorenal disease. Finally, we suggest that high intakes of fructose in African Americans may explain their greater predisposition to develop cardiorenal disease, and we provide a list of testable predictions to evaluate this hypothesis.

27 August 2008 in JAMA
Verified
Journal Article
Open access
PDF file
DFDaniel I. Feig
Daniel I. Feig
BSBeth Soletsky
Beth Soletsky
RJRichard J. Johnson
Richard J. Johnson
Hypertension is commonly associated with hyperuricemia.1,2 Early investigators proposed uric acid as having a causal role in hypertension.3-5 However, an elevation of uric acid in hypertension could be a consequence of reduced renal function, the use of diuretics, the presence of hyperinsulinemia and oxidative stress, or elevated renal vascular resistance, which are commonly present in this condition.6 As such, hyperuricemia is not considered a true risk factor for hypertension by the Joint National Committee,7 nor is it considered a cardiovascular risk factor by most expert organizations.8

9 May 2017 in Circulation
Verified
Journal Article
Closed access
PDF file
MVMiriam B. Vos
Miriam B. Vos
JKJill L. Kaar
Jill L. Kaar
JWJean A. Welsh
Jean A. Welsh
LHLinda V. Van Horn
Linda V. Van Horn
DFDaniel I. Feig
Daniel I. Feig
RJRachel K. Johnson
Rachel K. Johnson
Background: Poor lifestyle behaviors are leading causes of preventable diseases globally. Added sugars contribute to a diet that is energy dense but nutrient poor and increase risk of developing obesity, cardiovascular disease, hypertension, obesity-related cancers, and dental caries. Methods and Results: For this American Heart Association scientific statement, the writing group reviewed and graded the current scientific evidence for studies examining the cardiovascular health effects of added sugars on children. The available literature was subdivided into 5 broad subareas: effects on blood pressure, lipids, insulin resistance and diabetes mellitus, nonalcoholic fatty liver disease, and obesity. Conclusions: Associations between added sugars and increased cardiovascular disease risk factors among US children are present at levels far below current consumption levels. Strong evidence supports the association of added sugars with increased cardiovascular disease risk in children through increased energy intake, increased adiposity, and dyslipidemia. The committee found that it is reasonable to recommend that children consume ≤25 g (100 cal or ≈6 teaspoons) of added sugars per day and to avoid added sugars for children <2 years of age. Although added sugars most likely can be safely consumed in low amounts as part of a healthy diet, few children achieve such levels, making this an important public health target.